'Patient Experience Data' Section Added To US FDA Drug Reviews
Executive Summary
Genentech's hemophilia A treatment Hemlibra is among first products to include new dedicated section on patient experience data in its review documents as FDA begins implementing 21st Century Cures Act provision.
You may also be interested in...
US Patient-Focused Drug Development Meetings Changing With The Times
Meetings are now primarily hosted by external patient advocacy groups, with accelerated approval and surrogate endpoints making their way into discussions. Stakeholders want more transparency on how FDA uses PFDD reports, and one agency staffer suggests adding other types of expertise to the meetings.
US FDA Should Explain How It Uses Patient Experience Data In Drug Approvals – Report
Review documents do not always reflect whether PED was considered as part of an application, and stakeholders cannot easily determine how such data are used in the agency’s regulatory decision-making, an independent consultant review found.
Presence Of Patient Experience Data Table In FDA Drug Review Summaries ‘Inconsistent’
RTI Health Solutions researchers assessed US FDA review documents over past two years to gauge use of a tool meant to facilitate agency disclosures about what patient experience information it considered.